Drug intelligence / Profile preview

APL-2009

Development stage: Unknown
Lead developer: Apellis Pharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravitreal

Overview

APL-2009 is an investigational small interfering RNA (siRNA) designed to inhibit the production of complement component 3 (C3) directly within the eye. Developed by Apellis Pharmaceuticals (and potentially Biogen, per provided context), it is intended for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration. By utilizing RNA interference, APL-2009 aims to provide sustained suppression of the complement cascade at its central point, potentially offering a significantly reduced treatment burden compared to existing intravitreal therapies that require more frequent injections.

Targets

Beyond the preview

Go deeper on APL-2009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-2009.

Explore the full profile